Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut microbiota

Jonathan M. Pitt; Marie Vétizou; Ivo Gomperts Boneca; Patricia Lepage; Mathias Chamaillard; Laurence Zitvogel

doi:10.1080/2162402X.2015.1132137

Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut microbiota

Jonathan M. Pitt, Marie Vétizou, Ivo Gomperts Boneca, Patricia Lepage, Mathias Chamaillard, Laurence Zitvogel

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

51 Citations (Scopus)

Résumé

Although anticancer therapy with immune checkpoint blockers has seen unprecedented success, it fails to control neoplasia in most patients and often causes immune-related adverse events (irAEs). Our recent research shows the immunostimulatory and antitumor effects of CTLA-4 blockade depend on distinct Bacteroides species of the gut microbiota, signifying novel approaches to improve such immunotherapies.

langue originale	Anglais
Numéro d'article	e1132137
journal	OncoImmunology
Volume	6
Numéro de publication	1
Les DOIs	https://doi.org/10.1080/2162402X.2015.1132137
état	Publié - 2 janv. 2017

Accès au document

10.1080/2162402X.2015.1132137

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{24467b97dec541c1b2c447cf3fa9690f,

title = "Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut microbiota",

abstract = "Although anticancer therapy with immune checkpoint blockers has seen unprecedented success, it fails to control neoplasia in most patients and often causes immune-related adverse events (irAEs). Our recent research shows the immunostimulatory and antitumor effects of CTLA-4 blockade depend on distinct Bacteroides species of the gut microbiota, signifying novel approaches to improve such immunotherapies.",

keywords = "Anti-CTLA-4, Bacteroides, Cancer, Ipilimumab, Microbiome, Microbiota, T cell",

author = "Pitt, {Jonathan M.} and Marie V{\'e}tizou and Boneca, {Ivo Gomperts} and Patricia Lepage and Mathias Chamaillard and Laurence Zitvogel",

note = "Publisher Copyright: {\textcopyright} 2017 Taylor & Francis Group, LLC.",

year = "2017",

month = jan,

day = "2",

doi = "10.1080/2162402X.2015.1132137",

language = "English",

volume = "6",

journal = "OncoImmunology",

issn = "2162-4011",

number = "1",

}

TY - JOUR

T1 - Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut microbiota

AU - Pitt, Jonathan M.

AU - Vétizou, Marie

AU - Boneca, Ivo Gomperts

AU - Lepage, Patricia

AU - Chamaillard, Mathias

AU - Zitvogel, Laurence

PY - 2017/1/2

Y1 - 2017/1/2

N2 - Although anticancer therapy with immune checkpoint blockers has seen unprecedented success, it fails to control neoplasia in most patients and often causes immune-related adverse events (irAEs). Our recent research shows the immunostimulatory and antitumor effects of CTLA-4 blockade depend on distinct Bacteroides species of the gut microbiota, signifying novel approaches to improve such immunotherapies.

AB - Although anticancer therapy with immune checkpoint blockers has seen unprecedented success, it fails to control neoplasia in most patients and often causes immune-related adverse events (irAEs). Our recent research shows the immunostimulatory and antitumor effects of CTLA-4 blockade depend on distinct Bacteroides species of the gut microbiota, signifying novel approaches to improve such immunotherapies.

KW - Anti-CTLA-4

KW - Bacteroides

KW - Cancer

KW - Ipilimumab

KW - Microbiome

KW - Microbiota

KW - T cell

UR - http://www.scopus.com/inward/record.url?scp=85019259316&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2015.1132137

DO - 10.1080/2162402X.2015.1132137

M3 - Article

C2 - 28197360

AN - SCOPUS:85019259316

SN - 2162-4011

VL - 6

JO - OncoImmunology

JF - OncoImmunology

IS - 1

M1 - e1132137

ER -